---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-041035"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T11:49:11.798378+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics appoints Asif Ali as EVP, CFO effective April 18, 2022

## Summary
- Asif Ali, 48, appointed EVP, CFO; previously VP Finance & CAO at Theravance Biopharma (2018-2022) and VP Corp Controller at Depomed.
- Annual base salary $425,000; eligible for discretionary bonus up to 40% of base salary.
- Initial equity grant: option to purchase 82,500 shares (4-yr vest, 1-yr cliff) and 13,750 RSUs (4-yr equal installments).
- No family relationships with any executive officer or director; no material interests in reportable transactions.

## SEC filing metadata
- accession: 0001104659-22-041035
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/0001104659-22-041035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/tm2210916d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-041035
- JSON: https://secwatch.observer/filing/0001104659-22-041035.json
- Plain text: https://secwatch.observer/filing/0001104659-22-041035.txt

## Key facts
- Executive change
  Asif Ali was appointed as Executive Vice President, Chief Financial Officer at Protagonist Therapeutics, Inc.
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer
  source text: On March 25, 2022, the Board of Directors of Protagonist Therapeutics, Inc. (the “Company”) approved the appointment of Asif Ali, 48, to the position of Executive Vice President, Chief Financial Officer, effective on commencement of Mr. Ali’s employment with the Company (April 18, 2022).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/0001104659-22-041035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.